TwiFlow Thrombectomy Catheter sYstem for Acute Pulmonary Embolism (Twi-TYPE Study)

Acute Pulmonary Embolism Clinical Trial

— Twi-TYPE  

Official title:

A Multicenter Prospective Single-arm Study to Evaluate the Safety and Efficacy of a Novel Transcatheter Pulmonary Thrombectomy System Which Named 'TwiFlow' for Acute Pulmonary Embolism

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05792397
• Other study ID #: CHENXING-2022-05
• Status: Not yet recruiting
• Phase: N/A
• Start date: May 1, 2023
• Est. completion date: May 1, 2026

Study information

• Verified date: March 2023
• Source: Morningside (Nantong) Medical Co.,Ltd
• Contact: Ni Linyan, Manager
• Phone: +8613661929821
• Email: lyni[@]siriusmed.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

As a multicenter prospective single-arm clinical study, the investigators plan to recruit patients with acute pulmonary intravascular embolization from nationwide multi-center hospital organizations in China. The investigators use the production of transcatheter pulmonary artery bolt system which named 'TwiFlow Thrombectomy Catheter System' developed by the MorningSide (NanTong) medical device Co., LTD. on pulmonary artery interventional therapy to evaluating the efficacy and safety of this novel system in the treatment of patients with pulmonary intravascular embolization disease.

Description:

As a multicenter prospective single-arm clinical study, the investigators plan to evaluate the new production's efficacy and safety which named 'TwiFlow-Thrombectomy Catheter System'. This study will be carried out in nationwide multi-center hospital organizations in China. According to the statistical principle, the sample size of this study was estimated, and the final number of selected cases was 127. After screening, all subjects will be treated with transcatheter pulmonary artery thrombectomy system, and clinical follow-up will be conducted at 48 hours, 14 days and 30 days after surgery. Right Ventricular/Left Ventricular decline from baseline to 48 hours after surgery and the incidence of major adverse events (MAE) within 48 hours after surgery were used as primary endpoints. In instrument performance evaluation, the success rate of surgery, postoperative immediate target lesion embolus removal efficiency, pulmonary artery pressure changes before and after operation value, values of arterial oxygen partial pressure changes before and 14 days after operation, death rates related to the equipment in 48 hours after surgery, incident rate of bleeding in 48 hours after operation, postoperative clinical deterioration rate in 48 hours after surgery, postoperative pulmonary vascular injury incidence in 48 hours after surgery, the incidence of heart damage injury in 48 hours after surgery, all-cause death rate in 30 days after surgery, and symptomatic Pulmonary Embolization recurrence rate in 30 days after surgery were secondary endpoints.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 127
• Est. completion date: May 1, 2026
• Est. primary completion date: May 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. 18= age =75, no gender limitation;

2. patients clinically diagnosed as acute pulmonary embolism requiring pulmonary artery thrombosis clearance;

3. RV/LV ratio =0.9;

4. Duration of pulmonary embolism symptoms =14 days

5. Systolic blood pressure =90mmHg

6. Patients who agreed to participate in the study and voluntarily signed the informed consent.

Exclusion Criteria:

1. Target vessel diameter < 6.6mm;

2. Calcification, plaque or stenosis of target lesions;

3. Pulmonary arterial hypertension with peak pulmonary arterial pressure >70mmHg;

4. Vasopressor is required after infusion to maintain pressure =90mmHg;

5. Hematocrit < 28%;

6. Patients with left bundle branch block;

7. A history of chronic left heart failure and left ventricular ejection fraction=30%;

8. Patients with abnormal renal function (serum creatinine > 1.8 mg/dL or >159umol/L);

9. Patients with known coagulopathy or bleeding tendency (platelet<100×109/L, or INR> 3);

10. Patients who cannot receive antiplatelet or anticoagulant therapy;

11. Patients who underwent cardiovascular or pulmonary open surgery within 7 days before surgery;

12. Patients with intracardiac thrombosis;

13. Patients treated with extracorporeal membrane oxygenation;

14. Patients known to be allergic to contrast agents;

15. Patients with diseases that may cause difficulty in treatment and evaluation (such as malignant tumor, acute infectious disease, sepsis, general condition that cannot tolerate surgery, life expectancy less than 3 months, etc.);

16. Pregnant and lactating women;

17. Patients who are participating in clinical trials of other drugs or medical devices;

18. Other patients deemed unsuitable for the study by the investigator;

Related Conditions & MeSH terms

• Acute Pulmonary Embolism
• Embolism
• Pulmonary Embolism

Intervention

Device:
• TwiFlow-Thrombectomy Catheter System
Patients with acute pulmonary embolism and meeting the conditions of this clinical trial will accept the pulmonary embolism removal operation by the novel device named 'TwiFlow-Thrombectomy Catheter System'

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Morningside (Nantong) Medical Co.,Ltd

References & Publications (7)

Al-Hakim R, Bhatt A, Benenati JF. Continuous Aspiration Mechanical Thrombectomy for the Management of Submassive Pulmonary Embolism: A Single-Center Experience. J Vasc Interv Radiol. 2017 Oct;28(10):1348-1352. doi: 10.1016/j.jvir.2017.06.025. — View Citation

Moore K, Kunin J, Alnijoumi M, Nagpal P, Bhat AP. Current Endovascular Treatment Options in Acute Pulmonary Embolism. J Clin Imaging Sci. 2021 Jan 25;11:5. doi: 10.25259/JCIS_229_2020. eCollection 2021. — View Citation

Sista AK, Horowitz JM, Tapson VF, Rosenberg M, Elder MD, Schiro BJ, Dohad S, Amoroso NE, Dexter DJ, Loh CT, Leung DA, Bieneman BK, Perkowski PE, Chuang ML, Benenati JF; EXTRACT-PE Investigators. Indigo Aspiration System for Treatment of Pulmonary Embolism — View Citation

Tu T, Toma C, Tapson VF, Adams C, Jaber WA, Silver M, Khandhar S, Amin R, Weinberg M, Engelhardt T, Hunter M, Holmes D, Hoots G, Hamdalla H, Maholic RL, Lilly SM, Ouriel K, Rosenfield K; FLARE Investigators. A Prospective, Single-Arm, Multicenter Trial of — View Citation

Villalba L, Nguyen T, Feitosa RL Jr, Gunanayagam P, Anning N, Dwight K. Single-session catheter-directed lysis using adjunctive power-pulse spray with AngioJet for the treatment of acute massive and submassive pulmonary embolism. J Vasc Surg. 2019 Dec;70( — View Citation

Wible BC, Buckley JR, Cho KH, Bunte MC, Saucier NA, Borsa JJ. Safety and Efficacy of Acute Pulmonary Embolism Treated via Large-Bore Aspiration Mechanical Thrombectomy Using the Inari FlowTriever Device. J Vasc Interv Radiol. 2019 Sep;30(9):1370-1375. doi — View Citation

Yasin JT, Davis R, Saemi A, Regunath H, Krvavac A, Saboo SS, Bhat AP. Technical efficiency, short-term clinical results and safety of a large-bore aspiration catheter in acute pulmonary embolism - A retrospective case study. Lung India. 2020 Nov-Dec;37(6) — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Right Ventricular/Left Ventricular decline from baseline to 48 hours after surgery	Right Ventricular (RV) and Left Ventricular (LV) were recorded during the screening period and 48 hours after surgery by echocardiography or pulmonary artery CT (CTPA), and RV/LV and RV/LV reduction were calculated. The target RV/ LV reduction from baseline to 48 hours after surgery was at least 0.2.	before and 48 hours after surgery
Primary	The incidence of major adverse events (MAE) within 48 hours after surgery	The incidence of major adverse events (MAE) during and 48 hours after surgery was observed and recorded, and the incidence of MAE was calculated (referring to the definition of MAE). The target incidence of MAE 48 hours after surgery was less than 25%.; MAE events defined as those occurring within 48 hours of treatment include device-related death, massive bleeding, pulmonary vascular injury, and cardiac injury.; Haemorrhage: Disabling or life-threatening bleeding, or severe haemodynamic injury.; Pulmonary vascular injury: Defined as perforation or injury of a major pulmonary artery branch requiring surgical open surgical intervention.; Cardiac injury: Defined as heart injury requiring surgical open surgical intervention.	48 hours after surgery
Secondary	instrument performance evaluation	researchers try to evaluate the twi-system instrument' performance during the operation, so investigators will review whether the device system successfully performed the following steps: 1.Pulmonary thrombectomy system transport to the thromboembolic site (yes or not), 2.The thrombectomy stent was successfully deployed (yes or not), 3.the clot-plug is retracted successfully (yes or not), 4. the thrombectomy device safely removed from the body (yes or not), 5. Thrombus suction catheter delivers to the specified thromboembolic location (yes or not), 6.the thrombus suction catheter delivery system safely removed from the body (yes or not). The study predefine the answer"yes" to 1 point and "no" to 0 point, then investigators will calculate the total scores according above 6 steps and evaluate the twi-system instrument' performance during the operation.	intraoperative period
Secondary	the success rate of surgery	Surgical success was defined as successful thrombectomy without MAE.	intraoperative period
Secondary	pulmonary artery pressure changes before and after operation value	Changes in pulmonary artery pressure before and after operation = postoperative pulmonary artery pressure - preoperative pulmonary artery pressure	before the pulmonary intravascular embolization removal procedure began and after the embolization removal operation end immediately
Secondary	values of arterial oxygen partial pressure changes before and after operation	Preoperative and postoperative arterial oxygen partial pressure = 14 days postoperative arterial oxygen partial pressure - preoperative arterial oxygen partial pressure	before the pulmonary intravascular embolization removal procedure began and 14 days after surgery
Secondary	postoperative clinical deterioration rate in 48 hours after surgery	Clinical deterioration include instrumentation related events such as unplanned endotracheal intubation, mechanical ventilation, arterial hypotension (>1 hour) or shock, cardiopulmonary resuscitation, significant deterioration of oxygenation, and emergency surgical embolectomy.	48 hours after surgery]
Secondary	all-cause death rate in 30 days after surgery	all-cause death	30 days after surgery
Secondary	symptomatic Pulmonary Embolization recurrence rate in 30 days after surgery	patients occur pulmonary embolism again and represent related clinical symptoms	30 days after surgery

External Links

•   FLASH study Interim Results.